Compliance Rate
Compliance Rate
47.73%
Compliant submissions
21
Incompliant submissions
23
Total trials
44
My Organizations' Clinical Trials
Showing 250 of 271 entries
View as:
TAC-PF, AvastinĀ® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
Phase: N/A
Priority: Normal
Start: 01/31/07
End: 09/30/07
Due: 09/30/08
Phase: N/A
Priority: Normal
Start: 02/14/07
End: 02/01/19
Due: 02/01/20
Phase: N/A
Priority: Normal
Start: 01/31/01
End: 12/31/01
Due: 12/31/02
Phase: N/A
Priority: Normal
Start: 07/31/99
End: 06/30/04
Due: 06/30/05
Phase: N/A
Priority: Normal
Start: 12/04/07
End: 04/09/24
Due: 04/09/25
Phase: N/A
Priority: Normal
Start: 06/30/00
End: 08/31/03
Due: 08/31/04
Phase: N/A
Priority: Normal
Start: 07/17/03
End: 05/06/09
Due: 05/06/10
Phase: N/A
Priority: Normal
Start: 05/31/97
End: 05/31/02
Due: 05/31/03
Phase: N/A
Priority: Normal
Start: 12/31/00
End: 02/29/04
Due: 02/28/05
Phase: N/A
Priority: Normal
Start: 07/07/10
End: 08/07/13
Due: 08/07/14
Phase: N/A
Priority: Normal
Start: 03/18/03
End: 05/25/16
Due: 05/25/17
Phase: N/A
Priority: Normal
Start: 07/31/05
End: 09/30/09
Due: 09/30/10
Phase: N/A
Priority: Normal
Start: 09/30/03
End: 08/31/05
Due: 08/31/06
Phase: N/A
Priority: Normal
Start: 09/10/03
End: 08/15/07
Due: 08/15/08
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 04/30/14
Due: 04/30/15
Phase: N/A
Priority: Normal
Start: 03/27/08
End: 12/04/18
Due: 12/04/19
Phase: N/A
Priority: Normal
Start: 05/31/04
End: 03/31/05
Due: 03/31/06
Phase: N/A
Priority: Normal
Start: 03/27/07
End: 10/24/07
Due: 10/24/08
Phase: N/A
Priority: Normal
Start: 08/31/98
End: 06/30/00
Due: 06/30/01
Phase: N/A
Priority: Normal
Start: 12/06/02
End: 09/19/06
Due: 09/19/07
Phase: N/A
Priority: Normal
Start: 11/02/09
End: 08/16/16
Due: 08/16/17
Phase: N/A
Priority: Normal
Start: 01/08/13
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/30/05
End: 05/31/06
Due: 05/31/07
Phase: N/A
Priority: Normal
Start: 12/07/05
End: 10/03/08
Due: 10/03/09
Phase: N/A
Priority: Normal
Start: 05/31/12
End: 02/28/15
Due: 02/28/16